QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-femasys-maintains-13-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $13 price target.

 femasys-q1-2024-gaap-eps-017-beats-019-estimate-sales-271140k-miss-776500k-estimate

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10...

 chardan-capital-maintains-buy-on-femasys-maintains-12-price-target

Chardan Capital analyst Keay Nakae maintains Femasys (NASDAQ:FEMY) with a Buy and maintains $12 price target.

 hc-wainwright--co-maintains-buy-on-femasys-raises-price-target-to-12

HC Wainwright & Co. analyst Emily Bodnar maintains Femasys (NASDAQ:FEMY) with a Buy and raises the price target from $10...

 femasys-q4-eps-019-beats-021-estimate-sales-21311k-miss-24000k-estimate

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9....

 chardan-capital-reiterates-buy-on-femasys-maintains-12-price-target

Chardan Capital analyst Keay Nakae reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $12 price target.

 hc-wainwright--co-reiterates-buy-on-femasys-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $10 price target.

 first-lady-jill-biden-unveils-100m-in-federal-funding-to-support-rd---watch-out-for-these-women-health-stocks

Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of aware...

 femasys-inc-begins-fembloc-pivotal-trial-enrollment-at-stanford-medicine-fembloc-is-being-developed-as-a-first-
of-its-kind-non-surgical-permanent-birth-control-with-a-clearly-defined-us-regulatory-pathway

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the s...

 femasys-inc-completes-enrollment-of-femaseed-pivotal-trial-in-support-of-commercial-launch

- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 -ATLANTA, Nov. ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION